Rifampicin Reduces Plasma Concentrations of Moxifloxacin in Patients with Tuberculosis
Open Access
- 15 October 2007
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 45 (8), 1001-1007
- https://doi.org/10.1086/521894
Abstract
Background. The long duration of the current tuberculosis (TB) treatment is demanding and warrants the development of new drugs. Moxifloxacin shows pKeywords
This publication has 32 references indexed in Scilit:
- Effects of Rifampin and Multidrug Resistance Gene Polymorphism on Concentrations of MoxifloxacinAntimicrobial Agents and Chemotherapy, 2007
- Pharmacokinetics and Tolerability of a Higher Rifampin Dose versus the Standard Dose in Pulmonary Tuberculosis PatientsAntimicrobial Agents and Chemotherapy, 2007
- Moxifloxacin, Ofloxacin, Sparfloxacin, and Ciprofloxacin against Mycobacterium tuberculosis : Evaluation of In Vitro and Pharmacodynamic Indices That Best Predict In Vivo EfficacyAntimicrobial Agents and Chemotherapy, 2007
- Exposure to Rifampicin Is Strongly Reduced in Patients with Tuberculosis and Type 2 DiabetesClinical Infectious Diseases, 2006
- Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosisJournal of Antimicrobial Chemotherapy, 2005
- Selection of a Moxifloxacin Dose That Suppresses Drug Resistance inMycobacterium tuberculosis,by Use of an In Vitro Pharmacodynamic Infection Model and Mathematical ModelingThe Journal of Infectious Diseases, 2004
- Pharmacokinetic and Pharmacodynamic Issues in the Treatment of Mycobacterial InfectionsEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- Pharmacokinetics of RofecoxibClinical Pharmacokinetics, 2003
- The Physiological Kinetics of Nitrogen and the Prevention of Decompression SicknessClinical Pharmacokinetics, 2001
- Isoniazid Drug and Food InteractionsThe American Journal of the Medical Sciences, 1999